Nelarabine

證據等級: L5

預測適應症: 1 個

Nelarabine: From T-cell Acute Lymphoblastic Leukemia/Lymphoma to Relapsing-Remitting Multiple Sclerosis

One-Sentence Summary

Nelarabine (DrugBank DB01280) is a purine nucleoside analog chemotherapy agent used to treat T-cell acute lymphoblastic leukemia/lymphoma. The TxGNN model predicts it may be effective for relapsing-remitting multiple sclerosis (RRMS), but this prediction is currently supported by 0 clinical trials and 0 publications — it is a pure knowledge-graph inference with no direct empirical evidence.

Quick Overview

Item	Content
Original Indication	T-cell acute lymphoblastic leukemia/lymphoma (known use; not documented in Taiwan regulatory records — drug is not marketed in Taiwan)
Predicted New Indication	Relapsing-remitting multiple sclerosis
TxGNN Prediction Score	99.43%
Evidence Level	L5
Taiwan Market Status	Not marketed
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data (DrugBank original_moa) is not currently available for this drug (data gap DG002). Based on the model’s own rationale, nelarabine is a prodrug of ara-G, activated by deoxyguanosine kinase (dGK), and produces highly selective cytotoxicity against T-cells — this is the pharmacological basis for its approved use in T-cell leukemia/lymphoma.

RRMS is a T-cell–mediated (particularly Th17/CD8+) autoimmune demyelinating disease. TxGNN’s inference rests on a topological similarity in the knowledge graph — both conditions involve “T-cell” related nodes — rather than on any direct pharmacological or clinical validation of T-cell–selective cytotoxicity as a treatment strategy for MS.

Critically, the evidence pack itself flags a mechanistic contradiction: nelarabine has well-documented, severe, dose-limiting neurotoxicity (peripheral neuropathy, demyelination-like CNS symptoms, and even reversible posterior leukoencephalopathy syndrome). This is directly at odds with the neuroprotective goal of MS therapy, making the biological plausibility of this prediction low despite the high TxGNN score.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

US Market Information

Nelarabine is not marketed in Taiwan (0 licenses on record), so no NDA/product information is available.

Cytotoxicity

Item	Content
Cytotoxicity Classification	Conventional cytotoxic (purine nucleoside analog / antimetabolite)
Myelosuppression Risk	Please refer to the package insert warnings and precautions
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	CBC with differential, neurological examination (dose-limiting neurotoxicity has been reported), liver and renal function
Handling Protection	Standard cytotoxic/hazardous drug handling protocols apply

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN score is high, but evidence level is L5 — there are zero clinical trials or publications supporting nelarabine in RRMS, and the drug’s known dose-limiting neurotoxicity conflicts mechanistically with the neuroprotective goals of MS treatment.

To proceed, the following is needed:

TFDA label (warnings/contraindications) retrieval — currently a blocking data gap (DG001)
DrugBank-sourced mechanism of action confirmation (DG002)
Preclinical or mechanistic studies specifically evaluating T-cell–selective cytotoxic agents in demyelinating/autoimmune CNS disease models
Any real-world or case-level safety data addressing whether neurotoxicity risk is compatible with an MS patient population
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.